CME Group (CME) general counsel sells 3,291 shares in 10b5-1 trade

Rhea-AI Filing Summary

CME Group Inc. senior managing director and general counsel Jonathan L. Marcus reported an open-market sale of 3,291 shares of Class A common stock on March 17, 2026 at $313.37 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and he now holds 7,192 shares directly. This Form 4/A amendment only corrects the reported sale price; all other details from the original Form 4 remain the same.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marcus Jonathan L

(Last) (First) (Middle)

20 SOUTH WACKER DRIVE

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr MD General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/19/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	03/17/2026		S		3,291(1)	D	$313.37(2)	7,192	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 18, 2025.

2. This amendment is being filed to correct the price per share of the common stock sold on March 17, 2026, which was incorrectly reported on the original Form 4 filed on March 19, 2026 due to a clerical error. All other information in the original Form 4 remains unchanged.

Remarks:

	By: Margaret Austin Wright For: Jonathan L. Marcus	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CME (CME) report in this Form 4/A?

CME reported that senior managing director and general counsel Jonathan L. Marcus sold 3,291 shares of Class A common stock on March 17, 2026. The transaction was an open-market sale and left him holding 7,192 shares directly afterward.

At what price did the CME (CME) insider sell shares in this filing?

The insider sale was reported at a price of $313.37 per share. This Form 4/A specifically amends the prior filing to correct that per-share sale price while keeping all other transaction details unchanged from the original report.

How many CME (CME) shares does the insider hold after the sale?

Following the reported transaction, Jonathan L. Marcus directly holds 7,192 shares of CME Group Class A common stock. This post-transaction ownership figure reflects his position after selling 3,291 shares in the open market on March 17, 2026.

Was the CME (CME) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the March 17, 2026 sale was executed under a Rule 10b5-1 trading plan adopted on February 18, 2025. Such pre-arranged plans allow insiders to schedule trades in advance under predetermined conditions.

What is being corrected in this amended CME (CME) Form 4/A?

The amendment corrects the price per share of the common stock sold on March 17, 2026, which was previously reported incorrectly due to a clerical error. It confirms that all other information from the original Form 4 remains unchanged.

Does the CME (CME) Form 4/A include any derivative security transactions?

No. The reported activity involves only non-derivative Class A common stock. The derivative summary section shows no outstanding option or other derivative positions reported in this filing, indicating the amendment strictly concerns the common stock sale.